Aspen Neuroscience, Inc. has recently filed an SEC Form 3, revealing significant ownership changes by its Executive Chair, Hasnain Faheem. This filing, dated October 29, 2026, is crucial as it showcases the company's commitment to transparency and regulatory compliance in the competitive pharmaceutical preparations industry.

Background

Aspen Neuroscience, Inc. operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. The company is publicly traded under the ticker symbol ASPE. Its business address is located at 10835 Road to the Cure, Suite 100, San Diego, CA 92121. Recent filings include multiple Form 3 submissions on the same date, indicating active management of ownership disclosures.

What the Filing Says

The SEC filing indicates that Hasnain Faheem, as the reporting owner, holds 26,658 shares of common stock directly. Additionally, he has various holdings in convertible preferred stock, including:

14913 shares of Series A-1 Convertible Preferred Stock

14316 shares of Series A-2 Convertible Preferred Stock

7120 shares of Series C Convertible Preferred Stock

Faheem also holds stock options for 27,322 shares at an exercise price of $7.71 and 41,489 shares at $5.74, with different expiration dates. The filing reflects a direct ownership nature for the common stock and indirect ownership for the preferred stock.

Impact

This update may affect stakeholders, including investors and analysts, who closely monitor ownership structures in the pharmaceutical sector. The disclosure of such holdings is essential for understanding the alignment of management interests with those of shareholders. As Aspen Neuroscience continues to develop its offerings, these ownership details provide insight into the company's governance and strategic direction.

What's Next

The filing does not say what happens next. However, the continued disclosure of ownership changes may indicate ongoing developments within the company as it navigates the competitive landscape in the pharmaceutical preparations industry.